To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products

A Human Repeat Insult Patch Test (HRIPT) in Healthy Subjects to Assess the Cutaneous Irritation and Sensitization Potential of Three Developmental Cosmetic Facial Products

Sponsors

Lead Sponsor: GlaxoSmithKline

Source GlaxoSmithKline
Brief Summary

The aim of this study is to assess irritant or allergic response of 3 developmental cosmetic facial products following a conventional human repeated insult patch test methodology for 6 weeks.

Detailed Description

A randomized, single blind (evaluator), single-center, Human Repeat Insult Patch Test (HRIPT) study in healthy adult participants aged 18 to 65 years to evaluate the cutaneous irritation and contact sensitization potential of 3 cosmetic facial skincare products. The participants will undergo repeated cutaneous application of semi-occlusive patch of 3 cosmetic facial skincare products and a reference product as a negative control (saline solution). HRIPT is a long standing, standard method to determine whether exposure to a topical product will elicit a cutaneous (dermal) irritant or allergic response (sensitization) under exaggerated (occluded) conditions. Screening of the participants will be performed at Visit 1 (i.e. from Day 0 to Day 14). The study will progress in 3-phases: Induction phase, Rest Phase and Challenge Phase. The Induction phase will continue for 3 consecutive weeks (Visit 2 to Visit 10); at visit 2, the area for patch application will be designated between the scapula and waistline, away from the spinal mid-line. A controlled amount (0.02 milliliters per centimeters square [mL/cm^2]) of each study product will be randomly assigned within the patch system of each participant into the appropriate separate cell (3 cells for each of the test products and 1 cell for the saline solution). Each patch will remain in place for 48 (± 4) hours on weekdays and 72 (± 4) hours on weekend. Induction phase will be followed by 2-week (Visit 11) Rest phase; where there will be no product or patch applications. Rest phase is further followed by Challenge phase at week 6 (Visit 12 to Visit 15) in which a naïve area of the skin will be selected and a new patch with each of the cells filled with study products will be applied. After 48 (±4) hours of patch application, participants will return to the site, the patch will be removed, and subsequent test-site evaluations will be performed.

Overall Status Completed
Start Date August 30, 2019
Completion Date November 29, 2019
Primary Completion Date November 29, 2019
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 Day 40
Secondary Outcome
Measure Time Frame
Percentage of Participants With a Positive Reaction Score (Score of '+' or Greater) as Assessed by a Trained Evaluator Day 40
Enrollment 369
Condition
Intervention

Intervention Type: Other

Intervention Name: Serum

Description: Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square [mL/cm^2] of serum in an individual cell of patch)

Arm Group Label: Developmental Serum

Intervention Type: Other

Intervention Name: Lotion

Description: Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of lotion in an individual cell of patch)

Arm Group Label: Developmental Lotion

Intervention Type: Other

Intervention Name: Cream

Description: Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of cream in an individual cell of patch)

Arm Group Label: Developmental Cream

Intervention Type: Other

Intervention Name: Normal Saline

Description: Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of normal saline in an individual cell of patch)

Arm Group Label: Negative Control

Eligibility

Criteria:

Inclusion Criteria:

- Participant provision of a signed and dated in-formed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.

- A participant who is willing and able to comply with scheduled visits, treatment plan, and study procedures.

- A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, with no clinically significant or relevant abnormalities in medical history or upon dermal examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.

- A participant with Fitzpatrick phototype I to IV.

- A participant with healthy, intact skin at the proposed test area dorsum (below the shoulder, above the waist), as evaluated by a dermatologist, to ensure participant is free of clinically relevant dermatological conditions.

Exclusion Criteria:

- A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a GSK CH employee directly involved in the conduct of the study or a member of their immediate family.

- A participant who has participated in other studies involving investigational product(s) within 30 Days prior to study entry and/or during study participation.

- A participant who has participated in other studies including non-medicinal, cosmetic studies within 7 Days prior to study entry and/or during study participation.

- A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.

- A participant who is pregnant or intends to be-come pregnant during the study duration (self-reported).

- A participant who is breastfeeding.

- A participant with known or suspected intolerance or hypersensitivity to the study materials/product (or closely related com-pounds) or any of their stated ingredients, to hypoallergenic tape, or to the cotton patches.

- A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

- A participant unwilling or unable to comply with the Lifestyle Considerations; a) applying other product to test site, using cosmetics, b) changing dietary habits, c) getting patch test site wet, d) removing the patch, e) wearing tight or restrictive clothing that can remove patch, and f) engaging in activities that result in excessive sweating.

- A participant with current or recent (within last 6 months before the start of the study) history of atopic lesions and/or eczema.

- A participant with a history of allergic reactions to topical-use products, cosmetics or medications or their ingredients.

- A participant with any history of significant diseases or medical conditions known to alter skin appearance or physiologic response (e.g. uncontrolled diabetes) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site reaction.

- A participant considered immune-compromised.

- A participant with active dermatosis (local or disseminated) that might interfere with the results of the study.

- A participant currently using any medication which in the opinion of the investigator, may affect the evaluation of the investigational product or place the participant at undue risk.

- A participant who has used any of the following topical or systemic medications up to two weeks before the screening visit: immuno-suppressants, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDS, high dose aspirin), and/or corticosteroids.

- A participant who has used a transcutaneous electrical nerve stimulation (TENS) machine 1 day before the screening visit.

- A participant who has used oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month before the screening visit.

- A participant who has been vaccinated up to 1 month before the screening visit or is intending to receive a vaccination during their participation in the study.

- A participant with any skin marks on the back that might interfere with the evaluation of possible skin reactions (e.g. pigmentation disorders, open sores, pimples, cysts, vascular malformations, scars, tattoos, excessive hair, numerous freckles).

- A participant that intends bathing (in the sea or a pool), using sauna, or partaking in water sports, or activities that lead to intense sweating.

- A participant that is a prisoner or involuntary incarcerated.

- A participant from an indigenous tribe.

- A participant who has previously been enrolled in this study.

Gender: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
GSK Clinical Trials Study Director GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)
Location
Facility: GSK Investigational Site
Location Countries

Brazil

Verification Date

January 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Number Of Arms 4
Arm Group

Label: Developmental Serum

Type: Experimental

Description: The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.

Label: Developmental Lotion

Type: Experimental

Description: The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.

Label: Developmental Cream

Type: Experimental

Description: The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.

Label: Negative Control

Type: Placebo Comparator

Description: The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.

Patient Data Yes
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Intervention Model Description: The human repeated insult patch test (HRIPT) is a long standing, standard method to determine whether exposure to a topical product will elicit a cutaneous (dermal) irritant or allergic response (sensitization) under exaggerated (occluded) conditions.

Primary Purpose: Basic Science

Masking: Single (Outcomes Assessor)

Source: ClinicalTrials.gov